Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL481728 | 0.86 | S1PR1 (0.44) | NPC1RAB9AMETAP2S1PR1SMN1; SMN2 | |
| SCHEMBL10308946 | 0.84 | NOTUM (0.41) | NPC1RAB9AS1PR1HPGDSMN1; SMN2 | |
| SCHEMBL15942236 | 0.79 | TSHR (0.43) | NPC1RAB9AHPGDSMN1; SMN2TSHR | |
| SCHEMBL10726692 | 0.79 | ALDH1A1 (0.53) | NPC1RAB9AHPGDSMN1; SMN2TSHR | |
| SCHEMBL16181412 | 0.79 | NISCH (0.44) | — | |
| SCHEMBL10308948 | 0.79 | ALDH1A1 (0.45) | NPC1RAB9AHPGDSMN1; SMN2TSHR | |
| SCHEMBL16720953 | 0.77 | ALDH1A1 (0.33) | HPGD | |
| SCHEMBL26987745 | 0.76 | IDO1 (0.39) | METAP2IDO1 | |
| SCHEMBL26110328 | 0.74 | ADH5 (0.37) | NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL26953418 | 0.74 | METAP2 (0.34) | NPC1RAB9AMETAP2SMN1; SMN2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266850-A1 | SUBSTITUTED TOLYL FUNGICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266850-A1 | SUBSTITUTED TOLYL FUNGICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2015-09-24 | — | — | US | disclosed |
| EP-1846372-B1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20140039009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8592486-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| CN-101137624-B | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP | 2012-12-12 | — | — | CN | disclosed |
| US-20120225883-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-09-06 | — | — | US | disclosed |
| US-8202999-B2 | biphenyl and pyridylphenyl derivatives such as 2,6-Difluoro-N-[2'-methyl-5'-(pyridine-3-yl)-biphenyl-4-yl]-benzamide, used as immunosuppressants for the treatmet or prevent allergies, inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2012-06-19 | — | — | US | disclosed |
| EP-1846372-A4 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| CN-101137624-A | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP (US) | 2008-03-05 | — | — | CN | disclosed |
| EP-1846372-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006083477-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173006-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266850-A1 | SUBSTITUTED TOLYL FUNGICIDES | TH, CYP1B1, CYP1A1 | NPC1 693/4885RAB9A 516/4885METAP2 2930/4885 |
| US-20120225883-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR8, CXCR2 | NPC1 593/4885RAB9A 965/4885METAP2 1808/4885 |
| US-20060173006-A1 | Compounds for inflammation and immune-related uses | CXCL8, CCR8, CXCR2 | NPC1 593/4885RAB9A 965/4885METAP2 1808/4885 |
| US-20140039009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR8, CXCR2 | NPC1 593/4885RAB9A 965/4885METAP2 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.